CAPS community

Hier ist eine Auswahl von Informtionen von Patienten & Fachleuten, um die CAPS besser verstehen zu können.

CAPS Resource

Krankheit : Alle NOMID FCAS Muckle Wells

CAPS Häufig gestellte Fragen

Hier sind einige der am häufigsten gestellten Fragen und ihre Antworten :

Wenn Sie ein Patient oder Betreuer sind und eine Frage zu Leben mit CAPS, zu Behandlungen oder zu anderen relevante Informationen haben, senden Sie bitte Ihre E-Mail-Frage an [email protected] Wir werden diese an die Spezialisten weiterleiten, die sich bereit erklärt haben, von Zeit zu Zeit Ihre Fragen zu beantworten.

 

Sehen Sie hier alle FAQs

Was versteht man unter FCAS?

FCAS ist die Kurzform des familiären kälteinduzierten, auto-inflammatorischen Syndroms. Es kann auch FCAIS oder FCU (Familial Cold Urticaria) genannt werden. Es handelt sich dabei um eine erbliche ...

Tags: FCAS

Volle Antwort lesen

Was ist Muckle-Wells?

Muckle-Wells-Syndrom (MWS) ist ein von mehreren mit Cryopyrin assoziierten periodischen Syndromen (CAPS), die von Mutationen in den CIAS1/NLRP3-Genen verursacht werden. Diese Syndrome sind gekennze...

Tags: Muckle-Wells

Volle Antwort lesen

Was versteht man unter FCAS?

FCAS ist die Kurzform des familiären kälteinduzierten, auto-inflammatorischen Syndroms. Es kann auch FCAIS oder FCU (Familial Cold Urticaria) genannt werden. Es handelt sich dabei um eine erbliche ...

Volle Antwort lesen

Was ist NOMID?

NOMID ("Neonatal-onset multisystem inflammatory disease"), auch bekannt als CINCA ("chronic infantile neurologic cutaneous articular"), ist eine seltene, systemische, entzündlic...

Volle Antwort lesen

Was ist Muckle-Wells?

Muckle-Wells-Syndrom (MWS) ist ein von mehreren mit Cryopyrin assoziierten periodischen Syndromen (CAPS), die von Mutationen in den CIAS1/NLRP3-Genen verursacht werden. Diese Syndrome sind gekennze...

Volle Antwort lesen

CAPS Patientengruppen

Dies sind Patientenorganizationen, die Erfahrung und Können in CAPS Krankheiten haben. They are supporters of this website. Contact them for more information on their activities.

Siehe alle Patientengruppen

  • NOMID Alliance

    The NOMID Alliance is a 501 (c)(3) non-profit public charity dedicated to promoting awareness, proper diagnosis and treatment, and improved care for people with CAPS (Cryopyrin-Associated Periodic Syndromes) and other autoinflammatory syndromes.

    In Verbindung treten mit NOMID Alliance
  • AMWS/CINCA

    French patient association providing information and support to patients and carers living with Muckle-Wells Syndrome and CINCA/NOMID.

    In Verbindung treten mit AMWS/CINCA
  • Canadian CAPS Network

    About the Canadian CAPS Network Mission The mission of the Canadian CAPS Network (CCN) is to improve the lives of all those affected by Cryopyrin-Associated Periodic Syndromes (CAPS) and related disorders. Objectives •To improve awareness of CAPS and related disorders among the public, patients and family, clinicians, researchers, and policy makers. •To provide information and support to patients and families affected by CAPS and related disorders. •To encourage and support collaborative research into the causes and treatment of CAPS and related disorders toward improved diagnosis, treatment, and care. •To promote and support improved prevention, diagnosis, treatment and care for patients and families affected by CAPS and related disorders. •To provide a common voice for patients, families and supporters of CAPS and related disorders. •To serve as a forum for bringing together patients and families, healthcare professionals, researchers, industry, funders, and policy makers to raise funds and promote health policies that improve the lives of those affected by CAPS and related disorders.

    In Verbindung treten mit Canadian CAPS Network

Siehe alle Patientengruppen

CAPS Dokumente

Quellen, Dokumente und detaillierte Informationen zu on CAPS. In dieser Sektion können Sie Broschüren herunterladen, nach gedrucktem Material fragen oder hilfreiche Links finden.

Siehe alle Dokumente

CAPS Artikel

Letzte Artikel:

Siehe alle Artikel

Muckle-Wells Syndrome

Symptoms

Common symptoms of MWS include recurrent rashes beginning in infancy or early childhood, intermittent fevers, joint pain (usually with no apparent changes in tissue and cartilage), rec...

Lesen

Familial Cold Autoinflammatory Syndrome

Symptoms

Patients with FCAS experience mild to debilitating symptoms such as rash, fatigue, recurrent fever and chills, recurrent joint pain, and recurrent conjunctivitis (inflammation of the o...

Lesen

Neonatal-onset Multisystem Inflammatory Disease

Symptoms

In addition to fever, symptoms of NOMID involve the skin, CNS and joints. Skin rashes occur in all patients within the first six weeks of life and persist throughout their lives. CNS s...

Lesen

CAPS Veranstaltungen

Letzte Veranstaltungen:

Sehen Sie alle Veranstaltungen

  • Februar 2011

  • Rare Disease Day 2011

    On 28 Februar 2011

    February 28th 2011 will mark the fourth International Rare Disease Day coordinated by EURORDIS and organised with rare disease national alliances in 25 countries. On that day hundreds of patient organisations from more than 40 countries worldwide will be organising awareness-raising activities and converging around the slogan “Rare but Equal”.

    Mehr Info

CAPS Nachrichten der Gemeinschaft

  • -

    Four cases of Muckle-Wells syndrome within the same family
    News, publiziert vor 7 Tage

    Die Kopie ansehen


    ABSTRACT

    Muckle-Wells syndrome is a rare autosomal dominant disease that belongs to a group of hereditary febrile syndromes. It is characterized by recurrent and self-limited episodes of fever, urticaria, arthralgia, myalgia and conjunctivitis since childhood, which are related to exposure to cold temperatures. Lately, progressive sensorineural hearing loss occurs. Amyloidosis is the main complication and can be found in about 25% of the cases. It has been demonstrated that there is an association with mutations in the NLRP3 gene, which codifies cryopyrin, a protein responsible for regulating the production of proinflammatory cytokines, such as interleukin-1Beta. The authors report four cases of the disease within a family.

  • -

    La Respuesta al Canakinumab en el Tratamiento del CAPS dura 2 Añ
    News, publiziert vor etwa 1 Monat

    Die Kopie ansehen


    Article in SPANISH language:

    By: BRUCE JANCIN, Skin & Allergy News Digital Network

    GOTEBORG, SUECIA  - El bloqueo de la interleucina 1 (IL-1) con canakinumab aportó una remisión clínica rápida y constante a casi todos los niños y adultos con síndromes periódicos asociados a la criopirina (CAPS) que participaron en un extenso estudio de 2 años de duración.

  • -

    Anakinra Effective for Severe Muckle-Wells Syndrome
    News, publiziert vor 2 Monate

    Die Kopie ansehen


    The recombinant interleukin (IL)-1 receptor antagonist anakinra is safe and effective for severe Muckle-Wells syndrome, according to a report in the November 15th Arthritis & Rheumatism online. Reuters Health Information (Source: Medscape Medical News Headlines)

  • -

    Periodic fever syndromes in Eastern and Central European countries
    News, publiziert vor 2 Monate

    Die Kopie ansehen


    Objective

    To analyze the prevalence of diagnosed and suspected autoinflammatory diseases in Eastern and Central European (ECE) countries, with a particular interest on the diagnostic facilities in these countries.

    Methods

    Two different strategies were used to collect data on patients with periodic fever syndromes from ECE countries- the Eurofever survey and collection of data with the structured questionnaire.

    Results

    Data from 35 centers in 14 ECE countries were collected. All together there were 11 patients reported with genetically confirmed familial Mediterranean fever (FMF), 14 with mevalonate-kinase deficiency (MKD), 11 with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and 4 with chronic infantile neurological cutaneous and articular syndrome (CINCA). Significantly higher numbers were reported for suspected cases which were not genetically tested. All together there were 49 suspected FMF patients reported, 24 MKD, 16 TRAPS, 7 CINCA and 2 suspected Muckle-Wells syndrome (MWS) patients.

    Conclusions

    The number of genetically confirmed patients with periodic fever syndromes in ECE countries is very low. In order to identify more patients in the future, it is important to organize educational programs for increasing the knowledge on these diseases and to establish a network for genetic testing of periodic fever syndromes in ECE countries.

  • -

    Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response
    News, publiziert vor 3 Monate

    Die Kopie ansehen


    This link will take you to the full text article.

    Abstract:

    Cryopyrin-associated periodic syndrome (CAPS) is a rare hereditary inflammatory disorder encompassing a continuum of three phenotypes: familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease. Distinguishing features include cutaneous, neurological, ophthalmologic, and rheumatologic manifestations. CAPS results from a gain-of-function mutation of the NLRP3 gene coding for cryopyrin, which forms intracellular protein complexes known as inflammasomes. Defects of the inflammasomes lead to overproduction of interleukin-1, resulting in inflammatory symptoms seen in CAPS. Diagnosis is often delayed and requires a thorough review of clinical symptoms. Remarkable advances in our understanding of the genetics and the molecular pathway that is responsible for the clinical phenotype of CAPS has led to the development of effective treatments. It also has become clear that the NLRP3 inflammasome plays a critical role in innate immune defense and therefore has wider implications for other inflammatory disease states.

    Curr Allergy Asthma Rep. 2010 Nov 23;

    Authors: Yu JR, Leslie KS

  • -

    Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
    News, publiziert vor 4 Monate

    Die Kopie ansehen


    Status: Recruiting, Condition Summary: Cryopyrin-associated Periodic Syndromes (CAPS); Familial Cold Autoinflam Syn (FCAS); Muckle-wells Syn (MWS); Neonatal Onset Multisystem Inflam Disease (NOMID)

    Brief Summary

    Official Title: “An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients”

    The purpose of this observational study is to collect additional information regarding long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical practice.

    Study Type: Observational

    Study Design: Observational Model: Cohort, Time Perspective: Prospective

    Study Primary Completion Date: November 2014

  • -

    A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
    News, publiziert vor 5 Monate

    Die Kopie ansehen


    Objectives: - To determine the effectiveness of XOMA 052 as a treatment for inflammation in adults with the autoinflammatory diseases Familial Cold Autoinflammatory Syndrome (FCAS)/Muckle-Wells Syndrome (MWS) and Behcet's Disease.

    Eligibility: - FCAS/ MWS: Individuals at least 18 years of age who have a known history of the typical disease. - Behcet's Disease: Individuals at least 18 years of age who have evidence of active disease, such as oral or genital ulcers or eye disease.

    Status: Recruiting, Condition Summary: Muckle Wells Syndrome; Autoinflammatory; Behcet's Disease

  • -

    Democrat unites two families affected by rare syndrome - Dundalk Democrat
    News, publiziert vor 5 Monate

    Die Kopie ansehen


    Democrat unites two families affected by rare syndrome Hannah was diagnosed with Muckle Wells in November 2009 and Michele's nine-year-old daughter, Sophia, was diagnosed with the same syndrome last June. ...

  • -

    Swedish Orphan Biovitrum's Kineret(R) has Received Orphan Drug Designation in the USA
    News, publiziert vor 6 Monate

    Die Kopie ansehen


    Swedish Orphan Biovitrum (STO: SOBI) today announced that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to Kineret® for the treatment of cryopyrin-associated periodic syndromes (CAPS).
     

  • -

    Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS).
    News, publiziert vor 9 Monate

    Die Kopie ansehen

    The efficacy of canakinumab in the treatment of CAPS provides proof of concept that IL-1β is an important factor in the pathogenesis of this disorder. Canakinumab given at 150 mg per dose induced a complete response after the administration of a single dose in almost all the patients as well as inflammatory markers, and the effect appears to be sustained for up to at least 2 months between injections and continues to be effective with very little patient drop-out for longer periods. Some patients need higher doses (up to 300 mg) to induce a complete response. HRQoL and general mental and physical health and fatigue scores improved to the levels expected in the general population. The effect of canakinumab was similar in adults and children. To date, no deaths or life-threatening AEs have ocurred in CAPS
    patients treated with canakinumab and only mild AEs and symptoms were noted, none of which affected continuation of treatment. Still, there is a potentially higher risk for systemic infections and perhaps vertigo, especially in patients with MWS, which require special attention. The ability to administer canakinumab every 2 months with implications for compliance and minimal injection-site reactions is also attractive.